Collaboration
Nxera’s Partner Cancer Research UK to Present on Phase 1/2a Clinical Trial with Cancer Immunotherapy Drug HTL0039732 at ESMO
HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies Cancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing Phase 1/2a clinical trial o...
New therapy that targets and destroys tau tangles is a promising future Alzheimer’s disease treatment
Medical Research Council media release.
Cambridge Film Festival and Anglia Ruskin University forge a landmark educational partnership
The Cambridge Film Festival (CFF) and Anglia Ruskin University (ARU) have announced a new partnership that aims to enrich educational offerings and foster innovative opportunities within the film industry. ...
Inspire 2 Ignite launches innovative product, pioneering the future of educational gaming and intergenerational communication
St Neots - Inspire 2 Ignite announces the launch of its first product, Curious Conversation Blocks, a groundbreaking tool that redefines educational gaming and intergenerational communication. ...
Mission Street and BGO get go-ahead for 23-acre central Cambridge science district
CAMBRIDGE, UK - In a significant step forward for the UK’s aspirations to be a ‘science superpower’, specialist investor, developer and operator for the science and innovation sector Mission Street and BGO, a leading global real estate investment manager, received planning consent to de...
Marshall forges new relationship through first contract with U.S. Army
Marshall has won a contract to design and supply a rigid-walled expandable container enabling the U.S. Army’s Combat Capabilities Development Command Chemical Biological Center (DEVCOM CBC) to provide forensics and environmental capabilities to allies and partners. ...
Rail Gourmet uses Timestip multi-use indicators for enhanced food safety
Food waste reduced by a half.
Introducing Gluetacs Therapeutics to the UK market
Gluetacs Therapeutics (www.gluetacs.com), a pioneering biotech company located in the innovative Lin-gang Special Area of China (Shanghai) Pilot Free Trade Zone, is making significant strides in the field of targeted protein degradation, both in molecular glue (GLUE) and bifunctional ...
Cambridge 2030 school partnership wins award for collaboration
A long-term partnership between local secondary school, North Cambridge Academy (NCA), independent school group, Stephen Perse Cambridge, and major employer, Costello Medical, brokered by Cambridge 2030 CIC to help address some of the major challenges faced by the academy and its stud...